Premium
COMPLEMENT FACTORS AND THE GROWTH OF EHRLICH'S CARCINOMA
Author(s) -
Thunold S.,
Horseide V.,
Hartveit F.
Publication year - 1973
Publication title -
acta pathologica microbiologica scandinavica section b microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0365-5563
DOI - 10.1111/j.1699-0463.1973.tb02218.x
Subject(s) - zymosan , infiltration (hvac) , inflammation , carcinoma , globulin , complement system , chemistry , cellular infiltration , immunology , biology , endocrinology , medicine , immune system , biochemistry , physics , in vitro , thermodynamics
The subcutaneous growth of Ehrlich's carcinoma and the acute inflammatory reactions against it were investigated in mice treated with the following complement depleting agents: heat‐aggregated human gamma‐globulin (HAGG), zymosan, anti‐C1q and anti‐C3. In normal mice deposits of mouse C1q, C3 and IgG in and around small vessels adjacent to the tumour were paralleled by a marked inflammatory response with oedema and accumulation of leucocytes. In contrast, mice treated with zymosan showed reduced serum C3 levels, lack of C3 binding to walls of vessels and lack of leucocyte infiltration. Serum C1q levels were normal in zymosan treated mice. Moreover, HAGG and anti‐C1q reduced serum C1q significantly without affecting the inflammatory reactions. These findings emphazise the important role of C3 as a leucotactic factor. Mice depleted of C3 by zymosan showed decreased tumour size and tumour cell infiltration in addition to lack of inflammatory response. It is suggested that the availability of C3 is a determining factor in the establishment and early growth of this tumour.